In vitro susceptibility testing of yeasts to nystatin – low minimum inhibitory concentrations suggest no indication of in vitro resistance of Candida albicans, Candida species or non-Candida yeast species to nystatin

Pietro Nenoff,Daniela Koch,Claudia Neumeister,Constanze Krüger,Ulrich Schwantes

doi:10.15761/cmi.1000116

Abstract

In vitro susceptibility testing of yeasts to nystatin – low minimum inhibitory concentrations suggest no indication of in vitro resistance of Candida albicans, Candida species or non-Candida yeast species to nystatin

Highlights

The common use of azole antifungal agents, in particular oral fluconazole, and topical azoles, for the treatment of cutaneous and oral candidiasis, and possibly due to the use of azole fungicides in agricultural crop protection, has led to the emergence of azole and echinocandine resistance of clinical isolates of Candida (C.) albicans and other Candida species [1]
Minimum inhibitory concentrations (MIC) of nystatin against various yeast strains (Candida albicans, Candida glabrata and Candida parapsilosis) as determined by broth microdilution assay according to European Committee on Antimicrobial Susceptibility Testing (EUCAST)
Minimum inhibitory concentrations (MIC) of nystatin against various control strains as determined by broth microdilution assay according to EUCAST

Summary

Introduction

The common use of azole antifungal agents, in particular oral fluconazole, and topical azoles, for the treatment of cutaneous and oral candidiasis, and possibly due to the use of azole fungicides in agricultural crop protection, has led to the emergence of azole and echinocandine resistance of clinical isolates of Candida (C.) albicans and other Candida species [1]. An alternative therapeutic approach is the use of topical polyene antifungals such as amphotericin B or nystatin. Limited current data exists regarding Candida species which are resistant to polyene antifungals. A total of 201 clinical C. albicans isolates from Turkey investigated by Etest were found to be susceptible to amphotericin B [2]. In vitro susceptibility testing studies have shown a low percentage of Candida species isolated from HIV positive patients to be resistant to nystatin [3]

Methods

Results

Conclusion